



## Clinical trial results:

**Prevention of congenital cytomegalovirus infection in infants of mothers with primary cytomegalovirus infection during pregnancy. A randomised, open, controlled, multicentre and multinational study investigating efficacy and safety of Cytotect FH, nanometer filtered (BT094)**

### Summary

EudraCT number	2007-004692-19
Trial protocol	DE BE HU AT IT
Global end of trial date	22 December 2016

### Results information

Result version number	v1 (current)
This version publication date	13 December 2021
First version publication date	13 December 2021

### Trial information

#### Trial identification

Sponsor protocol code	963
-----------------------	-----

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Biotest AG
Sponsor organisation address	Landsteinerstr. 5, Dreieich, Germany, 63303
Public contact	Andrea Wartenberg-Demand, MD, PhD VP CCR&D Landsteinerstr. 5 63303 Dreieich, Biotest AG, 49 06103801497, andrea.wartenberg-demand@biotest.com
Scientific contact	Andrea Wartenberg-Demand, MD, PhD VP CCR&D Landsteinerstr. 5 63303 Dreieich, Biotest AG, 49 06103801497, andrea.wartenberg-demand@biotest.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	16 March 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	22 December 2016
Global end of trial reached?	Yes
Global end of trial date	22 December 2016
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

Prevention of congenital CMV infection in infants of mothers with primary CMV infection during pregnancy. The number (percentage) of newborns/foetuses with congenital CMV infection is defined as the primary efficacy parameter.

Protection of trial subjects:

none

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 March 2008
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Austria: 2375
Country: Number of subjects enrolled	Belgium: 3600
Country: Number of subjects enrolled	Germany: 8318
Country: Number of subjects enrolled	Hungary: 1024
Country: Number of subjects enrolled	Italy: 157
Worldwide total number of subjects	15474
EEA total number of subjects	15474

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	0
Adults (18-64 years)	15474
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Date of first enrolment: 08-OCT-2008; date of last completed: 22-DEC-2016

### Pre-assignment

Screening details:

Pregnant women, CMV-specific IgG seronegative pregnant women at Screening, Gestational age  $\leq 13$  w+6 d, 18 to 45 years of Age, written informed consent.

In total, 15,474 pregnant women were screened. Out of these, 9,535 pregnant women were randomized, to either Group A (BT094 treatment group) or Group B ("standard of care"), in a 1:1 ratio

### Period 1

Period 1 title	Screening
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Group A (BT094)

Arm description:

Regular CMV-Screening after randomization (only CMV-negative women)

Arm type	Experimental
Investigational medicinal product name	BT094
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Two doses of BT094 of 2 x 200 U/kg body weight (BW) intravenously at an interval of 14 days. The first dose had to be administered within 7 days after confirmed CMV seroconversion. A third administration 28 days after second administration was optional.

<b>Arm title</b>	Group B (standard of care)
------------------	----------------------------

Arm description:

No regular CMV-Screening after randomization (only CMV-negative subjects)

Arm type	No intervention
No investigational medicinal product assigned in this arm	

Number of subjects in period 1 <sup>[1]</sup>	Group A (BT094)	Group B (standard of care)
Started	4800	4735
Completed	4800	4735

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Only subjects that had been test seronegative for CMV entered screening phase

## Period 2

Period 2 title	Treatment period
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Group A (BT094)
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	BT094
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Two doses of BT094 of 2 x 200 U/kg body weight (BW) intravenously at an interval of 14 days. The first dose had to be administered within 7 days after confirmed CMV seroconversion. A third administration 28 days after second administration was optional.

<b>Arm title</b>	Group B (standard of care)
Arm description: -	
Arm type	No intervention
No investigational medicinal product assigned in this arm	

<b>Number of subjects in period 2<sup>[2]</sup></b>	Group A (BT094)	Group B (standard of care)
Started	45	35
Completed	45	35

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Only subjects with seroconversion during the study entered treatment period

## Period 3

Period 3 title	Follow-up (newborns)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

## Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Group A (BT094)
Arm description: -	
Arm type	No intervention
No investigational medicinal product assigned in this arm	
<b>Arm title</b>	Group B (standard of care)
Arm description: -	
Arm type	No intervention
No investigational medicinal product assigned in this arm	

<b>Number of subjects in period 3</b>	Group A (BT094)	Group B (standard of care)
Started	45	35
Completed	45	35

## Baseline characteristics

### Reporting groups

Reporting group title	Group A (BT094)
Reporting group description: Regular CMV-Screening after randomization (only CMV-negative women)	
Reporting group title	Group B (standard of care)
Reporting group description: No regular CMV-Screening after randomization (only CMV-negative subjects)	

Reporting group values	Group A (BT094)	Group B (standard of care)	Total
Number of subjects	4800	4735	9535
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	4800	4735	9535
From 65-84 years	0	0	0
85 years and over	0	0	0
Gender categorical Units: Subjects			
Female	4800	4735	9535
Male	0	0	0

## End points

### End points reporting groups

Reporting group title	Group A (BT094)
Reporting group description: Regular CMV-Screening after randomization (only CMV-negative women)	
Reporting group title	Group B (standard of care)
Reporting group description: No regular CMV-Screening after randomization (only CMV-negative subjects)	
Reporting group title	Group A (BT094)
Reporting group description: -	
Reporting group title	Group B (standard of care)
Reporting group description: -	
Reporting group title	Group A (BT094)
Reporting group description: -	
Reporting group title	Group B (standard of care)
Reporting group description: -	

### Primary: Number of CMV-infected fetuses and newborns

End point title	Number of CMV-infected fetuses and newborns
End point description:	
End point type	Primary
End point timeframe: Number of CMV-infected fetuses and newborns from seroconverted mothers. Confirmation of presence or absence of CMV infection was assessed by using PCR in urinalysis of the newborn, or by using PCR in the amniotic fluid.	

End point values	Group A (BT094)	Group B (standard of care)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	45	28		
Units: Number of CMV-infected fetuses and newb	16	13		

### Statistical analyses

Statistical analysis title	Primary Analysis
Comparison groups	Group A (BT094) v Group B (standard of care)



Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	> 0.05
Method	Fisher exact

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Treatment-emergent AEs were to be recorded from the start of treatment in group A and from the time of detected seroconversion of the mother in group B until last follow-up visit of the newborn in both groups.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	19.1

### Reporting groups

Reporting group title	Group A (BT094) mothers
Reporting group description: -	
Reporting group title	Group B (standard of care) mothers
Reporting group description: -	
Reporting group title	Group A (BT094) fetuses
Reporting group description: -	
Reporting group title	Group B (standard of care) fetuses
Reporting group description: -	
Reporting group title	Group A (BT094) newborn
Reporting group description: -	
Reporting group title	Group B (standard of care) newborn
Reporting group description: -	

Serious adverse events	Group A (BT094) mothers	Group B (standard of care) mothers	Group A (BT094) fetuses
Total subjects affected by serious adverse events			
subjects affected / exposed	15 / 45 (33.33%)	7 / 34 (20.59%)	6 / 45 (13.33%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			
subjects affected / exposed	0 / 45 (0.00%)	1 / 34 (2.94%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian adenoma			
subjects affected / exposed	0 / 45 (0.00%)	1 / 34 (2.94%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			

Hypertension			
subjects affected / exposed	1 / 45 (2.22%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Caesarean section			
subjects affected / exposed	9 / 45 (20.00%)	4 / 34 (11.76%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 9	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Failed trial of labour			
subjects affected / exposed	0 / 45 (0.00%)	1 / 34 (2.94%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postpartum haemorrhage			
subjects affected / exposed	1 / 45 (2.22%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breech presentation			
subjects affected / exposed	1 / 45 (2.22%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complication of delivery			
subjects affected / exposed	1 / 45 (2.22%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foetal distress syndrome			
subjects affected / exposed	1 / 45 (2.22%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Premature labour			
subjects affected / exposed	4 / 45 (8.89%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Foetal acidosis			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Neonatal respiratory failure			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Nuclear magnetic resonance imaging brain abnormal			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	2 / 45 (4.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otoacoustic emissions test abnormal			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Perineal injury			
subjects affected / exposed	1 / 45 (2.22%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skull fracture			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			

subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Foetal cystic hygroma			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypersplenism congenital			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital central nervous system anomaly			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital cytomegalovirus infection			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kidney duplex			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subependymal nodular heterotopia			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Bradycardia foetal			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Nonreassuring foetal heart rate pattern			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral ventricle dilatation			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Splenomegaly			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	2 / 45 (4.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Haemorrhoids			
subjects affected / exposed	1 / 45 (2.22%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatomegaly			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	2 / 45 (4.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Proteinuria			
subjects affected / exposed	1 / 45 (2.22%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelocaliectasis			

subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Musculoskeletal and connective tissue disorders</b>			
Hypotonia neonatal			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
Cytomegalovirus infection			
subjects affected / exposed	0 / 45 (0.00%)	1 / 34 (2.94%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 45 (2.22%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenovirus infection			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus hepatitis			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovirus infection			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastroenteritis			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Group B (standard of care) fetuses	Group A (BT094) newborn	Group B (standard of care) newborn
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 34 (5.88%)	10 / 45 (22.22%)	5 / 34 (14.71%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			



subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian adenoma			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Caesarean section			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Failed trial of labour			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postpartum haemorrhage			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breech presentation			
subjects affected / exposed	1 / 34 (2.94%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complication of delivery			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Foetal distress syndrome	subjects affected / exposed	1 / 34 (2.94%)	0 / 45 (0.00%)	0 / 34 (0.00%)
	occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Premature labour	subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foetal acidosis	subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions				
Pyrexia	subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	0 / 34 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders				
Neonatal respiratory failure	subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	1 / 34 (2.94%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations				
Nuclear magnetic resonance imaging brain abnormal	subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otoacoustic emissions test abnormal	subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	0 / 34 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications				
Perineal injury				

subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skull fracture			
subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Foetal cystic hygroma			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypersplenism congenital			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital central nervous system anomaly			
subjects affected / exposed	0 / 34 (0.00%)	2 / 45 (4.44%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital cytomegalovirus infection			
subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	2 / 34 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kidney duplex			
subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subependymal nodular heterotopia			

subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Bradycardia foetal			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nonreassuring foetal heart rate pattern			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral ventricle dilatation			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Splenomegaly			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Haemorrhoids			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatomegaly			

subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Proteinuria			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelocaliectasis			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Hypotonia neonatal			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cytomegalovirus infection			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenovirus infection			
subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			
subjects affected / exposed	0 / 34 (0.00%)	2 / 45 (4.44%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cytomegalovirus hepatitis			
subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovirus infection			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media			
subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 2 %

<b>Non-serious adverse events</b>	Group A (BT094) mothers	Group B (standard of care) mothers	Group A (BT094) fetuses
Total subjects affected by non-serious adverse events			
subjects affected / exposed	30 / 45 (66.67%)	9 / 34 (26.47%)	7 / 45 (15.56%)
Surgical and medical procedures			
Caesarean section			
subjects affected / exposed	9 / 45 (20.00%)	4 / 34 (11.76%)	0 / 45 (0.00%)
occurrences (all)	9	4	0
Pregnancy, puerperium and perinatal conditions			
Premature labour			
subjects affected / exposed	5 / 45 (11.11%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	5	0	0
Uterine contractions during pregnancy			
subjects affected / exposed	2 / 45 (4.44%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	2	0	0
Jaundice neonatal			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Breech presentation			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Foetal distress syndrome			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	5 / 45 (11.11%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	5	0	0
Pyrexia			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Sleep disorder			

subjects affected / exposed occurrences (all)	2 / 45 (4.44%) 2	0 / 34 (0.00%) 0	0 / 45 (0.00%) 0
Investigations			
Nuclear magnetic resonance imaging brain abnormal			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	2 / 45 (4.44%)
occurrences (all)	0	0	2
Foetal heart rate abnormal			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Perineal injury			
subjects affected / exposed	2 / 45 (4.44%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	2	0	0
Vulval laceration			
subjects affected / exposed	0 / 45 (0.00%)	1 / 34 (2.94%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Congenital, familial and genetic disorders			
Foetal cystic hygroma			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Congenital central nervous system anomaly			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Congenital cytomegalovirus infection			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Bradycardia foetal			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	2 / 45 (4.44%)
occurrences (all)	0	0	2
Nervous system disorders			
headache			
subjects affected / exposed	3 / 45 (6.67%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	3	0	0
Cerebral ventricle dilatation			



subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	0 / 34 (0.00%) 0	2 / 45 (4.44%) 3
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 45 (4.44%)	1 / 34 (2.94%)	0 / 45 (0.00%)
occurrences (all)	3	1	0
Anaemia of pregnancy			
subjects affected / exposed	1 / 45 (2.22%)	1 / 34 (2.94%)	0 / 45 (0.00%)
occurrences (all)	1	1	0
Splenomegaly			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	2 / 45 (4.44%)
occurrences (all)	0	0	2
Ear and labyrinth disorders			
Middle ear effusion			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Astigmatism			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Retinal haemorrhage			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Dyspepsia			
subjects affected / exposed	3 / 45 (6.67%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	3	0	0
Haemorrhoids			
subjects affected / exposed	2 / 45 (4.44%)	1 / 34 (2.94%)	0 / 45 (0.00%)
occurrences (all)	2	1	0
Nausea			
subjects affected / exposed	2 / 45 (4.44%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	2	0	0
Constipation			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			

subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	0 / 34 (0.00%) 0	0 / 45 (0.00%) 0
Gastrooesophageal reflux disease subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	0 / 34 (0.00%) 0	0 / 45 (0.00%) 0
Hepatobiliary disorders Hepatomegaly subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	0 / 34 (0.00%) 0	2 / 45 (4.44%) 2
Skin and subcutaneous tissue disorders Eczema subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	0 / 34 (0.00%) 0	0 / 45 (0.00%) 0
Rash subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	0 / 34 (0.00%) 0	0 / 45 (0.00%) 0
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	1 / 34 (2.94%) 1	0 / 45 (0.00%) 0
Infections and infestations Bronchitis subjects affected / exposed occurrences (all)	2 / 45 (4.44%) 2	0 / 34 (0.00%) 0	0 / 45 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	5 / 45 (11.11%) 5	0 / 34 (0.00%) 0	0 / 45 (0.00%) 0
Bronchiolitis subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	0 / 34 (0.00%) 0	0 / 45 (0.00%) 0
Conjunctivitis subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	0 / 34 (0.00%) 0	0 / 45 (0.00%) 0
Ear infection subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	0 / 34 (0.00%) 0	0 / 45 (0.00%) 0

Gastroenteritis			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Varicella			
subjects affected / exposed	0 / 45 (0.00%)	0 / 34 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Cytomegalovirus infection			
subjects affected / exposed	0 / 45 (0.00%)	1 / 34 (2.94%)	0 / 45 (0.00%)
occurrences (all)	0	1	0

<b>Non-serious adverse events</b>	Group B (standard of care) fetuses	Group A (BT094) newborn	Group B (standard of care) newborn
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 34 (11.76%)	36 / 45 (80.00%)	19 / 34 (55.88%)
Surgical and medical procedures			
Caesarean section			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Pregnancy, puerperium and perinatal conditions			
Premature labour			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Uterine contractions during pregnancy			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Jaundice neonatal			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	2 / 34 (5.88%)
occurrences (all)	0	0	2

Breech presentation subjects affected / exposed occurrences (all)	1 / 34 (2.94%) 1	0 / 45 (0.00%) 0	0 / 34 (0.00%) 0
Foetal distress syndrome subjects affected / exposed occurrences (all)	1 / 34 (2.94%) 0	0 / 45 (0.00%) 0	0 / 34 (0.00%) 0
General disorders and administration site conditions			
Fatigue subjects affected / exposed occurrences (all)	0 / 34 (0.00%) 0	0 / 45 (0.00%) 0	0 / 34 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	0 / 34 (0.00%) 0	3 / 45 (6.67%) 3	0 / 34 (0.00%) 0
Psychiatric disorders			
Sleep disorder subjects affected / exposed occurrences (all)	0 / 34 (0.00%) 0	0 / 45 (0.00%) 0	0 / 34 (0.00%) 0
Investigations			
Nuclear magnetic resonance imaging brain abnormal subjects affected / exposed occurrences (all)	0 / 34 (0.00%) 0	0 / 45 (0.00%) 0	0 / 34 (0.00%) 0
Foetal heart rate abnormal subjects affected / exposed occurrences (all)	1 / 34 (2.94%) 1	0 / 45 (0.00%) 0	0 / 34 (0.00%) 0
Injury, poisoning and procedural complications			
Perineal injury subjects affected / exposed occurrences (all)	0 / 34 (0.00%) 0	0 / 45 (0.00%) 0	0 / 34 (0.00%) 0
Vulval laceration subjects affected / exposed occurrences (all)	0 / 34 (0.00%) 0	0 / 45 (0.00%) 0	0 / 34 (0.00%) 0
Congenital, familial and genetic disorders			
Foetal cystic hygroma subjects affected / exposed occurrences (all)	1 / 34 (2.94%) 1	0 / 45 (0.00%) 0	0 / 34 (0.00%) 0
Congenital central nervous system			

anomaly			
subjects affected / exposed	0 / 34 (0.00%)	2 / 45 (4.44%)	1 / 34 (2.94%)
occurrences (all)	0	2	1
Congenital cytomegalovirus infection			
subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	2 / 34 (5.88%)
occurrences (all)	0	1	2
Cardiac disorders			
Bradycardia foetal			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
headache			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Cerebral ventricle dilatation			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Anaemia of pregnancy			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Splenomegaly			
subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	1 / 34 (2.94%)
occurrences (all)	0	1	1
Ear and labyrinth disorders			
Middle ear effusion			
subjects affected / exposed	0 / 34 (0.00%)	7 / 45 (15.56%)	1 / 34 (2.94%)
occurrences (all)	0	7	1
Eye disorders			
Astigmatism			
subjects affected / exposed	0 / 34 (0.00%)	2 / 45 (4.44%)	1 / 34 (2.94%)
occurrences (all)	0	2	1
Retinal haemorrhage			

subjects affected / exposed occurrences (all)	0 / 34 (0.00%) 0	2 / 45 (4.44%) 2	0 / 34 (0.00%) 0
Gastrointestinal disorders			
Dyspepsia			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	2 / 34 (5.88%)
occurrences (all)	0	1	2
Diarrhoea			
subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	1 / 34 (2.94%)
occurrences (all)	0	1	1
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 34 (0.00%)	2 / 45 (4.44%)	0 / 34 (0.00%)
occurrences (all)	0	2	0
Hepatobiliary disorders			
Hepatomegaly			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Eczema			
subjects affected / exposed	0 / 34 (0.00%)	3 / 45 (6.67%)	0 / 34 (0.00%)
occurrences (all)	0	3	0
Rash			
subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	1 / 34 (2.94%)
occurrences (all)	0	1	1
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0

Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 34 (0.00%)	5 / 45 (11.11%)	2 / 34 (5.88%)
occurrences (all)	0	5	2
Bronchiolitis			
subjects affected / exposed	0 / 34 (0.00%)	2 / 45 (4.44%)	0 / 34 (0.00%)
occurrences (all)	0	3	0
Conjunctivitis			
subjects affected / exposed	0 / 34 (0.00%)	2 / 45 (4.44%)	0 / 34 (0.00%)
occurrences (all)	0	3	0
Ear infection			
subjects affected / exposed	0 / 34 (0.00%)	6 / 45 (13.33%)	2 / 34 (5.88%)
occurrences (all)	0	7	3
Gastroenteritis			
subjects affected / exposed	0 / 34 (0.00%)	2 / 45 (4.44%)	0 / 34 (0.00%)
occurrences (all)	0	2	0
Otitis media			
subjects affected / exposed	0 / 34 (0.00%)	5 / 45 (11.11%)	4 / 34 (11.76%)
occurrences (all)	0	7	5
Rhinitis			
subjects affected / exposed	0 / 34 (0.00%)	2 / 45 (4.44%)	1 / 34 (2.94%)
occurrences (all)	0	2	1
Upper respiratory tract infection			
subjects affected / exposed	0 / 34 (0.00%)	4 / 45 (8.89%)	4 / 34 (11.76%)
occurrences (all)	0	4	4
Varicella			
subjects affected / exposed	0 / 34 (0.00%)	1 / 45 (2.22%)	1 / 34 (2.94%)
occurrences (all)	0	1	1
Cytomegalovirus infection			
subjects affected / exposed	0 / 34 (0.00%)	0 / 45 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
07 January 2008	Cytotect Biotest was introduced as optional off-Label Treatment in Group B for ethical reasons instead of the investigational product BT094 due to regulatory reasons.
30 June 2014	Introduction of planned recruitment stop after approval of amendment. Change in the recording of Adverse Events for Group B.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported